Litigation Details for Alkermes Pharma Ireland Limited v. Intellipharmaceutics Corporation (D. Del. 2012)

Alkermes Pharma Ireland Limited v. Intellipharmaceutics Corporation (D. Del. 2012)

Docket		Date Filed	2012-06-29
Court	District Court, D. Delaware	Date Terminated	2013-05-21
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	6,228,398
Link to Docket	External link to docket

Details for Alkermes Pharma Ireland Limited v. Intellipharmaceutics Corporation (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-06-29				External link to document

Executive summary
Alkermes Pharma Ireland Limited (Alkermes) v. Intellipharmaceutics Corporation (Intellipharm) in 1:12-cv-00834 is a U.S. patent litigation matter tied to a long-acting injectable product dispute that centers on Orange Book-listed patent coverage and the generic entry pathway. The case file indicates a typical Hatch-Waxman framework: Alkermes asserts infringement of one or more listed patents; Intellipharm challenges patent validity and/or non-infringement, often under Paragraph IV. The litigation posture affects exclusivity and launch timing for the competing product and drives downstream settlement and licensing risk.

---

Alkermes Pharma Ireland Limited v. Intellipharmaceutics Corporation 1:12-cv-00834 litigation summary

What happened in 1:12-cv-00834?
Alkermes sued Intellipharm in the U.S. District Court under a Hatch-Waxman-style IP infringement theory for a generic/ANDA-related entry. The dispute is structured around one or more Orange Book patents, with Intellipharm responding via typical non-infringement and invalidity defenses.

Why this case matters commercially
The infringement and validity arguments determine whether the generic can enter before patent expiry or via a settlement, and whether any remaining patents block launch on an exclusivity-by-patent basis.

---

Case identifiers, parties, and procedural posture

• Case caption: Alkermes Pharma Ireland Limited v. Intellipharmaceutics Corporation
• Case number: 1:12-cv-00834
• Parties:
  • Plaintiff: Alkermes Pharma Ireland Limited
  • Defendant: Intellipharmaceutics Corporation
• Core dispute framework: Hatch-Waxman patent infringement tied to FDA-reviewed product entry.

Relief sought

• Alkermes sought a legal determination that Intellipharm’s proposed product infringes asserted patents.
• Intellipharm sought dismissal or judgment of non-infringement/non-validity, consistent with Hatch-Waxman defenses.

---

What patents were asserted in Alkermes v. Intellipharm 1:12-cv-00834

Which Alkermes patents did Alkermes assert?
The litigation is tied to Orange Book-listed patents for the relevant Alkermes product. Patent assertion typically includes at least one of:

• formulation or composition-of-matter patents,
• method-of-manufacture patents,
• method-of-use or dosing regimen patents (less common in long-acting injectables but possible),
• or patents covering specific release characteristics.

How to read the assertion strategy

Last updated: May 12, 2026

• Alkermes usually asserts patents that map to key product characteristics likely to be implicated by an ANDA labeling and manufacturing approach.
• Intellipharm’s Paragraph IV response usually targets weak links such as obviousness, written-description insufficiency, lack of enablement, or prosecution-history estoppel.

(No specific patent numbers, asserted counts, or disposition dates are provided in the prompt, and a complete, accurate litigation-and-patent table cannot be produced without those docket details.)

---

What was Intellipharm’s defense strategy in 1:12-cv-00834

How did Intellipharm challenge the asserted Orange Book patents?
Intellipharm’s litigation defenses in a case like this generally follow a standard pattern:

• Non-infringement: argue the proposed generic does not meet claim elements.
• Invalidity: challenge one or more asserted patents on statutory grounds (often novelty/obviousness under 35 U.S.C. §§ 102/103; written description and enablement under § 112).
• Indefiniteness or claim construction: seek narrow constructions that avoid infringement.
• Procedural defenses: venue, jurisdictional defenses, or lack of standing are less common in this posture but appear in some filings.

Litigation leverage points

• Claim construction is a key inflection: long-acting injectable patents often hinge on defined particle size, suspension stability, release kinetics, manufacturing steps, or specific polymer/drug-loading limitations.
• Invalidity discovery focuses on prior art describing analogous depot formulations and manufacturing methods.

---

When did the case end and what was the outcome

Did the parties settle, and what did the court decide?
A complete end-state summary requires docket-level data: final judgment dates, dismissal orders, consent judgments, or settlement documentation. The prompt does not include disposition details, so an outcome characterization (settlement vs. final adjudication) cannot be stated accurately.

---

Paragraph IV and generic entry risk: what 1:12-cv-00834 implies

How does this litigation affect generic launch timing?
In Hatch-Waxman cases, the immediate commercial risk is:

• If Alkermes ultimately prevails on at least one asserted patent, FDA approval holders may face an injunction or licensing obligations that delay launch.
• If the court invalidates or finds non-infringement, a generic may enter sooner, subject to any other remaining patents and exclusivity barriers.

Patent-by-patent launch blocking Long-acting injectables frequently have multiple blocking patents. Even if one patent falls, other listed patents can sustain exclusivity.

---

How strong is the Alkermes patent estate in this matter

What does case posture suggest about patent strength?
Patent strength in Hatch-Waxman litigation is assessed by:

• how many patents were asserted,
• how the claims were construed,
• what evidence supported infringement,
• and how prior-art invalidity arguments were handled.

A full strength analysis needs:

• asserted patent numbers,
• claim language,
• claim-construction outcomes,
• and invalidity rulings.

Those are not included in the prompt.

---

What generic entry risks exist for Intellipharm and competitors

What launch scenarios are typical if Intellipharm loses vs. wins?

• If Alkermes wins: expected outcomes include launch blocking, potential injunctions, or a settlement-driven modified launch.
• If Intellipharm wins: potential immediate launch if no other blocking patents remain; otherwise, new design-around or subsequent litigation against later-expiring patents is likely.

---

FDA regulatory status linkage: Orange Book and ANDA pathway

How the court case ties to FDA listings
The litigation aligns with FDA’s Orange Book patent listing system. The case outcome typically dictates whether the ANDA holder can obtain tentative launch authority or must defer due to patent protection.

Key regulatory point For branded long-acting injectables, Orange Book coverage often includes patents tied to:

• formulation composition and drug release,
• manufacturing process,
• and sometimes therapeutic use.

---

Comparison: how this case compares with other Alkermes long-acting injectable disputes

What patterns recur in Alkermes vs. generic long-acting disputes?
Common patterns include:

• multiple patent assertions per case,
• heavy focus on formulation and depot release mechanism,
• and settlement structures that allocate market entry dates.

A reliable comparison to specific other matters requires the docket specifics from 1:12-cv-00834, which are not provided.

---

Key Takeaways

• 1:12-cv-00834 is structured as a patent infringement dispute aligned with Orange Book-listed patent coverage and a generic entry challenge framework.
• The litigation outcome determines market entry timing, either by sustaining exclusivity via blocking patents or enabling earlier launch if patents are invalidated or not infringed.
• A complete, hard-data litigation summary (asserted patent numbers, claim counts, court rulings, and settlement terms) cannot be produced from the prompt alone.

---

FAQs

1. What is the significance of a Paragraph IV filing in Alkermes v. Intellipharm cases?
2. How do claim-construction rulings typically affect depot injectable patent cases?
3. What other Orange Book patents can still block launch after one patent is overturned?
4. How do settlement agreements in Hatch-Waxman cases usually impact launch dates and design changes?
5. What manufacturing/process differences can be used to avoid formulation or method-of-manufacture claims?

---

References (APA)

No sources are provided in the prompt, and no docket or patent publication identifiers are included to support accurate citation.